Valuation: Altimmune, Inc.

Market Cap 593M 519M 479M 442M 839M 56.57B 853M 5.72B 2.25B 27.87B 2.23B 2.18B 95.81B P/E 2026 *
-4.53x
P/E 2027 * -4.02x
Enterprise Value 210M 184M 170M 157M 297M 20.04B 302M 2.03B 795M 9.87B 789M 772M 33.94B EV / Sales 2026 *
51,247x
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day-2.24%
1 week-3.48%
Current month+0.33%
1 month+16.86%
3 months-5.86%
6 months-24.13%
Current year-15.51%
1 week 2.93
Extreme 2.93
3.3
1 month 2.58
Extreme 2.58
3.4
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Chairman 78 01/01/2018
Director/Board Member 74 01/08/2004
Director/Board Member 58 01/09/2003
Date Insider Type Main position Quantity % Market Cap.
05-01Free

Director

48,800 0.0251%
05-01Free

Director

48,800 0.0251%
05-01Free

Director

48,800 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
-2.24%-3.48%-30.68%-11.34% 593M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.83%-0.38%+45.81%+130.90% 24.18B
Weighted average by Cap. -0.91%-1.46%+54.83%+137.39%

Financials

2026 *2027 *
Net sales 4.1K 3.59K 3.31K 3.06K 5.8K 391K 5.89K 39.52K 15.52K 193K 15.39K 15.06K 662K -
Net income -112M -97.78M -90.19M -83.3M -158M -10.66B -161M -1.08B -423M -5.25B -420M -411M -18.06B -139M -122M -112M -104M -197M -13.28B -200M -1.34B -527M -6.54B -523M -511M -22.49B
Net Debt -383M -335M -309M -285M -542M -36.53B -551M -3.69B -1.45B -18B -1.44B -1.41B -61.87B -256M -224M -207M -191M -362M -24.41B -368M -2.47B -969M -12.03B -961M -940M -41.35B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
10/07/26 $3.050 -2.24% 2,992,854
09/07/26 $3.120 +0.32% 2,876,992
08/07/26 $3.110 +2.98% 3,520,264
07/07/26 $3.020 -1.95% 4,619,754
06/07/26 $3.080 -2.53% 4,348,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.050USD
Average target price
15.45USD
Spread / Average Target
+406.56%

Quarterly revenue - Rate of surprise